Clinical research from the University of Catania, Italy has demonstrated a positive benefit to glaucoma patients from the oral administration of PEA (palmitoyl-ethanolamide), a shorter and fully saturated fatty acid amide analogue of the endogenous endocannabinoid, anadamide (AEA). PEA is found in most mammalian tissues and is known to possess anti-inflammatory, anti-nociceptive and anti-convulsant properties. The research, conducted as a prospective randomized cross-over clinical trial on 42 patients with either primary open angle glaucoma (POAG) or ocular hypertension (OH) demonstrated a clear reduction in intraocular pressure (IOP) following oral PEA administration (300mg tablets) twice a day for 2 months.